Strengthening Digital Health: Navigating the FDA Medical Device Cybersecurity Guidance and Mandatory SBOMs

FDA Medical Device Cybersecurity Guidance: Enforcing Section 524B of the FD&C Act to Secure Connected Devices via Strict SBOM Requirements for Medical Devices

As medical devices become increasingly interconnected through hospital networks, wireless configurations, and cloud infrastructure, they face a rising wave of sophisticated digital threats. In response to these vulnerabilities, the U.S. FDA finalized its comprehensive FDA medical device cybersecurity guidance, titled "Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions." This regulatory document establishes that robust cybersecurity controls are no longer optional—they are an indispensable component of proving a medical device’s overall safety and effectiveness.

A driving force behind this regulatory enforcement is Section 524B of the FD&C Act, which was signed into law via the Consolidated Appropriations Act. Under Section 524B of the FD&C Act, any sponsor submitting a marketing application for a "cyber device" (a device that contains software and has the capability to connect to the internet or other networks) must provide specific, verifiable assurances that the device is resilient against cyber threats. One of the most critical elements of this legal mandate is the strict implementation of SBOM requirements for medical devices, which forces manufacturers to provide a transparent, detailed inventory of all software components used within the system.

An electronic Software Bill of Materials (SBOM) acts as a comprehensive ingredient list, capturing commercial, open-source, and off-the-shelf software elements. Under the active FDA medical device cybersecurity guidance, failure to provide a sufficient SBOM can lead directly to a "Refuse to Accept" (RTA) decision, halting the premarket review process before it even begins. To comply with SBOM requirements for medical devices and secure market clearance, manufacturers must not only document every software dependency but also establish clear post-market vulnerability management plans, ensuring that security patches can be deployed rapidly and securely throughout the device's entire commercial lifecycle.

Source: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cybersecurity-medical-devices-quality-management-system-considerations-and-content-premarket